Pharmaceutical Industry 9 – 15 March: Featuring Katalyze Data, SAS, Theolytics and HUTCHMED
- Katalyze Data and SAS have developed DementAI, a UK-built artificial intelligence system designed to help identify Alzheimer’s disease risk earlier through existing clinical records.
- Theolytics has secured €8 million in Horizon Europe 2025 funding to support its phase 2 OCTOPOD-IV trial for THEO-260 in advanced ovarian cancer.
- HUTCHMED has dosed the first patient in a global phase 1/2a trial of HMPL-A580, a first-in-class antibody-targeted therapy conjugate for advanced solid tumours.
A Week of Sharp Progress for Data-Led Diagnosis and Precision Oncology
The pharmaceutical industry continues to move at speed, but not all progress comes in the same form. Some advances are measured in molecules and trial doses; others begin with better use of the information already sitting inside healthcare systems.
Taken together, recent developments involving Katalyze Data, SAS, Theolytics and HUTCHMED show how modern healthcare innovation is increasingly being driven by two forces at once: smarter identification of disease and more precise intervention once it is found.
From Alzheimer’s disease to ovarian cancer and advanced solid tumours, the common thread is clear. Whether the goal is to spot risk earlier, attack cancer more selectively or open up new treatment pathways for patients with limited options, the direction of travel is towards technologies that are more targeted, more integrated and more clinically actionable.
Katalyze Data and SAS Push Earlier Alzheimer’s Detection with DementAI
Among the most striking announcements is the emergence of DementAI, a new UK-developed artificial intelligence system created by consultancy Katalyze Data as part of the SAS Hackathon 2025.
The system is being positioned as a potential breakthrough in the earlier identification of Alzheimer’s disease, with the aim of reducing the number of people who are not formally diagnosed until symptoms have already progressed significantly.
That matters because dementia remains the leading cause of death in the United Kingdom, while a substantial number of people living with the condition are still thought to lack a formal diagnosis. For clinicians and families alike, that gap creates a difficult reality: warning signs may already be present, yet specialist referral and support can come too late to make the fullest possible difference.
DementAI is designed to tackle that problem by detecting risk signals already embedded within existing clinical records.
According to retrospective analysis conducted by the team, the tool could help identify Alzheimer’s disease up to around two years earlier than current routes. In practical terms, that could allow patients to access assessment, planning and support at a point when interventions may still be more meaningful.
Turning Fragmented Clinical Information into Actionable Insight
What gives DementAI particular weight is not just the predictive ambition behind it, but the way it has been built.
Rather than creating yet another isolated digital layer, the prototype connects stages that clinicians often manage separately, from data analysis through to model deployment within decision pathways. In other words, it is intended as an end-to-end working system, not simply an academic concept.
The platform uses information that health providers already hold, including structured medical records, brain activity data and unstructured clinical information, while also drawing on synthetic data where appropriate to support development.
By blending these different signals, the system aims to detect subtle patterns of decline that might be easy to miss in brief consultations or within fragmented care journeys.
Importantly, DementAI was recognised as the Health Care & Life Sciences category winner at the SAS Hackathon 2025, and its workflow has been designed with governance in mind. Clinicians are not simply handed a flag; they are given a transparent rationale for why a patient has been identified.
In sensitive healthcare settings, that explainability is not a luxury. It is fundamental to adoption.
The principal consultant at Katalyze Data framed the challenge in stark terms, describing dementia care as a race against time. The emphasis was not on prediction for prediction’s sake, but on buying patients time by surfacing signals that are already hiding in plain sight.
SAS, meanwhile, underlined that synthetic data, agentic AI concepts and governance are the elements that make this type of innovation usable at scale, particularly in healthcare where trust, safety and accountability are non-negotiable.
The next step is a critical one: the team is now seeking engagement with NHS Trusts to explore pilot deployments that could validate the model’s real-world impact and help reduce diagnostic delays.
Theolytics Secures Major Horizon Europe Backing for THEO-260
While DementAI points to the future of earlier detection, Theolytics represents another essential arm of pharmaceutical innovation: the creation of more sophisticated therapies for patients facing severe disease.
The Oxford-based biotechnology company has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025, following a competitive and rigorous review process.
The funding will support the company’s phase 2 OCTOPOD-IV clinical trial, which is evaluating THEO-260, a novel therapeutic candidate developed for advanced ovarian cancer.
The programme stands out for its dual-action strategy, targeting not only cancer cells themselves but also cancer-associated fibroblasts, a key part of the tumour-supporting stroma that can help shield disease from effective treatment.
This is a particularly important area of focus in stroma-rich solid cancers, where the tumour microenvironment can actively undermine therapeutic success. By pursuing both oncolytic and what the company describes as ‘CAF-lytic’ activity, Theolytics is aiming to address a significant unmet need using a mechanism designed to do more than simply attack the obvious tumour mass.
International Collaboration and a Clear Clinical Development Path
The grant application was coordinated with several international partners, including The Institute of Cancer Research in London and the Clínica Universidad de Navarra, reinforcing the collaborative depth behind the programme.
Two thirds of the funds will go directly to Theolytics to advance the phase 2a expansion trial, with a focus on patients with high-grade serous ovarian or endometrioid cancer.
The company’s Chief Scientific Officer and Co-founder said the award validates both the scientific rationale behind THEO-260 and the broader potential of its mechanism of action.
By integrating advanced translational analyses into the clinical trial design, the company intends to clinically demonstrate how the treatment works and generate the data needed to move the programme forward with confidence.
The OCTOPOD-IV trial is a first-in-human study designed to assess safety and preliminary efficacy, while also determining the recommended phase 2 dose. Academic and clinical partners have echoed the significance of the approach.
At The Institute of Cancer Research, the view is that targeting the stroma and inducing immune activity in the suppressed tumour microenvironment could open the door to an important new treatment option for patients with advanced solid tumours.
At the Clínica Universidad de Navarra, the focus is even more immediate: women with advanced ovarian cancer still face a serious shortage of effective options, and any genuine therapeutic advance would carry profound clinical value.
HUTCHMED Advances HMPL-A580 into Global Phase 1/2a Development
Elsewhere in oncology, HUTCHMED has announced the start of a global phase 1/2a clinical trial for HMPL-A580, its second antibody-targeted therapy conjugate, in patients with unresectable, advanced or metastatic solid tumours across China and the United States.
The first patient was dosed on 4 March 2026, marking an important milestone for the programme.
HMPL-A580 is described as a first-in-class ATTC that links a highly selective PI3K/PIKK inhibitor payload to an anti-EGFR antibody through a cleavable linker. That design is central to the rationale behind the treatment.
EGFR is widely expressed across multiple solid tumour types and plays a well-established role in tumour growth and progression. By combining EGFR targeting with payload delivery aimed at the PAM pathway, the therapy is intended to create a more potent anti-tumour response.
Preclinical work has suggested that inhibition of the PAM pathway may act synergistically with anti-EGFR therapy, with further data set to be presented at an upcoming scientific meeting.
The early-stage clinical study is multicentre and open label, assessing safety, tolerability, pharmacokinetics, immunogenicity and early signs of efficacy.
A Platform Strategy Built for Broader Cancer Utility
The phase 1 component of the trial will determine the maximum tolerated dose and the recommended dose for expansion. The phase 2a stage will then further define safety and preliminary anti-tumour activity in selected solid tumours while identifying the dose to take into the next phase of development. The study is listed under NCT07396584.
Beyond the individual candidate, HUTCHMED is also making a broader platform statement. Its ATTC platform combines monoclonal antibodies with proprietary small-molecule inhibitor payloads to create dual mechanisms of action.
According to the company, this sets the approach apart from traditional antibody-drug conjugates by pairing targeted therapies in a way designed to achieve synergistic anti-tumour effects and more durable responses in preclinical models.
The promise is not only better tumour accessibility, but also reduced off-tumour toxicity and greater compatibility with chemotherapy and immunotherapy combinations.
Built on more than two decades of targeted therapy development, the platform is intended to support a wide range of cancer candidates by using antibody-guided delivery and tumour-specific payload release to overcome some of the longstanding limitations associated with conventional small-molecule inhibitors.
What This Means for Pharmaceutical Manufacturing and Pharmaceutical Production
For pharmaceutical manufacturing and pharmaceutical production, this cluster of developments sends a clear message: the sector is evolving beyond volume and scale alone, and towards precision, integration and platform efficiency.
In practical terms, that means manufacturers must increasingly support not only the production of advanced therapeutics, but also the highly specialised processes, quality systems and supply chains that sit behind biologics, conjugates, translational diagnostics and data-enabled clinical decision tools.
In the case of AI systems such as DementAI, the manufacturing implication is not traditional factory output, but the industrialisation of validated digital tools that can be safely deployed within governed clinical environments.
For companies like Theolytics and HUTCHMED, the impact is more direct. Novel oncology products often require complex development pathways, tightly controlled production standards, sophisticated analytical support and cross-border coordination between research, trial and manufacturing teams.
As more therapies are designed around tumour biology, payload delivery and biomarker-led development, pharmaceutical production will need to become ever more agile, specialised and evidence-rich. The winners will be those able to combine scientific complexity with scalable, compliant execution.
Conclusion
Taken together, the latest moves from Katalyze Data, SAS, Theolytics and HUTCHMED illustrate a pharmaceutical industry that is not standing still.
One strand of innovation is focused on finding disease earlier by making better use of the data already available. Another is centred on building more intelligent, more selective therapies for patients with urgent unmet need.
Both are pushing in the same direction: towards healthcare that is faster to recognise danger, smarter in how it responds, and more precise in the treatments it brings forward.
Whether through an AI model designed to buy Alzheimer’s patients valuable time, a funded ovarian cancer trial aimed at reshaping the tumour microenvironment, or a first-in-class conjugate platform entering global development, the message is unmistakable. The future of the pharmaceutical industry will belong to solutions that do not merely add novelty, but deliver usable, clinically meaningful progress.
News Credits:
AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
Things you may also like: